HC Wainwright Boosts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $16.00

Larimar Therapeutics (NASDAQ:LRMR) had its target price raised by HC Wainwright from $15.00 to $16.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Larimar Therapeutics’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.91) EPS, FY2026 earnings at ($2.10) EPS and FY2027 earnings at ($1.57) EPS.

A number of other analysts have also recently issued reports on the company. Robert W. Baird lowered their target price on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. Truist Financial assumed coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective for the company. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Price Performance

Shares of NASDAQ:LRMR opened at $2.38 on Tuesday. The stock has a market cap of $151.54 million, a price-to-earnings ratio of -2.07 and a beta of 0.99. The company has a 50 day moving average of $3.10 and a 200-day moving average of $5.16. Larimar Therapeutics has a one year low of $2.19 and a one year high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16). Equities research analysts anticipate that Larimar Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LRMR. BNP Paribas Financial Markets bought a new position in shares of Larimar Therapeutics in the fourth quarter valued at $25,000. Algert Global LLC acquired a new stake in Larimar Therapeutics in the fourth quarter valued at $47,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Larimar Therapeutics in the 4th quarter valued at about $52,000. Graham Capital Management L.P. bought a new stake in Larimar Therapeutics in the fourth quarter valued at approximately $54,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Larimar Therapeutics in the fourth quarter valued at approximately $58,000. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.